Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
Condition(s):AL Amyloidosis; Light Chain (AL) Amyloidosis; Systemic Light Chain DiseaseLast Updated:January 17, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):AL Amyloidosis; Light Chain (AL) Amyloidosis; Systemic Light Chain DiseaseLast Updated:January 17, 2024Recruiting
Condition(s):Renal FailureLast Updated:June 24, 2005Completed
Condition(s):Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell CancerLast Updated:January 13, 2016Completed
Condition(s):Community Acquired Pneumonia; Complicated Skin and Soft Tissue InfectionLast Updated:March 26, 2024Completed
Condition(s):Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and UreterLast Updated:May 17, 2011Completed
Condition(s):Acute Kidney InjuryLast Updated:July 6, 2017Unknown status
Condition(s):Acute Kidney Injury; ICU; Postoperative PatientsLast Updated:November 30, 2021Completed
Condition(s):Hypertension, RenalLast Updated:February 27, 2023Recruiting
Condition(s):Chronic Kidney FailureLast Updated:July 8, 2015Completed
Condition(s):Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2Last Updated:December 6, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.